Abstract 4828
Background
Metastatic disease to the lung is one of the most common life-threatening complications of cancer and can be seen with most types of cancer. Apatinib, a tyrosine kinase inhibitor targeting VEGFR-2, has shown efficacy in lung cancer. And the preclinical data also showed plasma concentration of apatinib was high in the lung. This cancer registry study aims to make an exploratory assessment of the efficacy and safety of apabinib in lung metastases.
Methods
Between 2015/05 and 2018/03, this study recorded all patients with advanced cancers in our hospital, with apatinib 500 mg or 250 mg being given. Tumor response assessment and survival analysis were performed.
Results
For a total of 103 patients, 30 had no lung metastases, and 73 had lung metastases, among which most were bone sarcoma (56%) and soft-tissue sarcoma (37%) metastases to lung. Among 57 evaluable patients with lung metastases, 2 achieved CR, 29 achieved PR, and the ORR was 54%. In 11 evaluable patients with no lung metastases, no patient achieved CR, 3 patients achieved PR, and the ORR was 27%. For patients with lung metastases, the mPFS was 12.9 months (95%CI, 8.6-14.9 months), mOS was 21.9 months (95% CI, 15.9-31.3 months). For patients with no lung metastases, the mPFS was 6.0 months (95%CI, 4.6-NE months), the mOS was 10.7 months (95% CI, 5.2-NE months). In lung metastatic patients who received apatinib 500mg, the ORR and DCR were, respectively, 55.1% and 89.8%; when treated with apatinib 250mg, the ORR and DCR were 20% and 80%. When Apatinib was used as first line treatment, the ORR and DCR were respectively 64% and 88%; in second line treatment, the ORR and DCR were respectively 42% and 84%, and when apatinib was used in third line treatment, the ORR and DCR were 33% and 100%. For patients with lung metastases, 89.2% patients experienced adverse events (AEs); the most frequent AEs were hand-foot syndrome (21.6%), diarrhea (20%), hypertension (24.3%) and albuminuria (9.4%).
Conclusions
Based on this exploratory analysis, for bone sarcoma and soft-tissue sarcoma with lung metastases, apatinib 500mg showed promising trends in efficacy and safety profile. An expansion study will be needed.
Clinical trial identification
Legal entity responsible for the study
Chongqi Tu.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1449 - Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy. The importance of Ki-67 and molecular subtype.
Presenter: Bernardo Rapoport
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4023 - The accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in clinically node positive breast cancer patients: A single institution experience
Presenter: Narges Sistany Allahabadi
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4707 - Index BRCA1/2 testing under a multidisciplinary program
Presenter: Duarte Machado
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3393 - BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
Presenter: Alex Friedlaender
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3175 - PALB2 germ-line mutations in Russian breast cancer patients: identification of recurrent alleles and analysis of phenotypic characteristics of the tumors
Presenter: Evgeny Imyanitov
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3027 - Landscape of germline mutations in hereditary breast and ovarian cancer (HBOC) patients in Russia revealed by target panel sequencing
Presenter: Elena Shagimardanova
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4963 - Lynch syndrome-associated hereditary mutations cause breast and ovarian cancer: results from Russian Heredetary Oncogenomics project
Presenter: Marat Gordiev
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2916 - Impact of deleterious germline BRCA mutations, addition of taxanes and use of adjuvant endocrine therapy (ET) on anti-müllerian hormone (AMH) levels in early breast cancer (EBC) patients treated by adjuvant chemotherapy (CT)
Presenter: Nathalie OLYMPIOS
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2400 - Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study
Presenter: Esther Pohl
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1345 - BRCA1/BRCA2 Predictive Genetic Testing in an Irish Population: A Missed Opportunity
Presenter: David O Reilly
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract